Nelly Kuklin

Nelly Kuklin has a diverse and extensive work experience in the pharmaceutical industry. Nelly is currently serving as the Senior Vice President of Discovery Biology and Translational Sciences at Nirogy Therapeutics since April 2022. Prior to this, they worked at Compass Therapeutics LLC as the Vice President of Immunology from November 2019 to April 2022. Nelly also held the position of Sr. Director Research at Gemini Therapeutics from September 2018 to November 2019.

Nelly's earlier experience includes their role as a Rare Disease program leader at Alexion Pharmaceuticals, Inc. from 2014 to 2018, where they led cross-functional teams for new targets identification and managed biomarker plans for 9 programs. Nelly also prepared clinical documents for FDA approval. Before that, they had a long tenure at Merck, where they served in various roles including Director Head of Pharmacology Department Sirna/Merck, Program lead - Senior Research Fellow- Oncology Biologics, and Senior Research Immunologist; Research Fellow in Immunology, Infectious Diseases, and Vaccines. During their time at Merck, they managed a group of 17 researchers and contributed to the development of immunology and oncology-related projects.

Overall, Nelly Kuklin has demonstrated expertise in discovery biology, translational sciences, immunology, and rare diseases throughout their career in the pharmaceutical industry.

Nelly Kuklin's education history includes a post-doctoral fellowship at Stanford University School of Medicine from 1998 to 2000. During this time, they focused on intestinal lymphocyte homing and immunity to rotavirus (RV) infections. Prior to their post-doctoral fellowship, they pursued a Ph.D. at the University of Tennessee, Knoxville, from 1992 to 1997. Their research during their Ph.D. studies centered around the role of mucosal immunity in HSV infection, as well as the development of novel noninvasive immunization strategies for induction.